KOMZIFTI (ziftomenib), the first and only once-daily oral menin inhibitor for adult patients with R/R AML with a susceptible NPM1 mutation who have no satisfactory alternative treatment options, has ...

Genetix Biotherapeutics Inc. today announced real-world data from the commercial implementation of ZYNTEGLOtm and LYFGENIAtm, first-in-class ex vivo gene addition therapies for the treatment of ...

Oral presentation from pooled analyses of the IMerge population suggests that treatment-emergent cytopenias may reflect on-target effects associated with meaningful clinical outcomes, including hemogl ...

Mark Selby reflects on his ‘extra special’ UK Championship triumph as the two finalists react to his 10th Triple Crown title.

National Signing Day is in the rearview, and Rivals is looking back at the 2026 class beginning with the nation’s top ...